Old Web
English
Sign In
Acemap
>
authorDetail
>
Mario Pietrini
Mario Pietrini
Medicine
Internal medicine
General surgery
Oncology
Nivolumab
4
Papers
68
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (4)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
External validation of EPIC's Risk of Unplanned Readmission model, the LACE+ index and SQLape as predictors of unplanned hospital readmissions: A monocentric, retrospective, diagnostic cohort study in Switzerland.
2021
PLOS ONE
Aljoscha Benjamin Hwang
Guido Schuepfer
Mario Pietrini
Stefan Boes
Show All
Source
Cite
Save
Citations (0)
P3.07-001 Nivolumab for Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer: A Cost-Effectiveness Analysis including PD-L1 Testing: Topic: Therapy and Economics
2017
Journal of Thoracic Oncology
Klazien Matter-Walstra
Matthias Schwenkglenks
Stefan Aebi
Konstantin J. Dedes
Joachim Diebold
Mario Pietrini
Dirk Klingbiel
Roger von Moos
Oliver Gautschi
Show All
Source
Cite
Save
Citations (1)
A cost-effectiveness analysis of nivolumab versus docetaxel for advanced nonsquamous NSCLC including PD-L1 testing
2016
Journal of Thoracic Oncology
Klazien Matter-Walstra
Matthias Schwenkglenks
Stefan Aebi
Konstantin Dedes
Joachim Diebold
Mario Pietrini
Dirk Klingbiel
Roger von Moos
Oliver Gautschi
Show All
Source
Cite
Save
Citations (66)
Primary non-Hodgkin lymphoma in the pterygopalatine fossa. A peculiar diagnosis with a minimally invasive endoscopic approach
2014
Annals of Hematology
Veronica Seccia
Mario Pietrini
T. Briganti
Gabriele Buda
Show All
Source
Cite
Save
Citations (1)
1